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Introduction
Over the last 5 years, immunotherapy has become one of 
the backbones for cancer treatment, showing significant 
improvement in prognosis for several malignancies. 
Currently, in clinical practice, we have several immune 
checkpoint inhibitors targeting cytotoxic T lymphocyte 
associated antigen 4 (CTLA4), programmed cell death 1 
(PD-1) and programmed death ligand 1 (PD-L1), while 
several other drugs, directed toward different co-inhibitory 
or co-stimulatory molecules, are under evaluation (1). 
CTLA-4 is the first immune checkpoint to be clinically 
targeted. Ipilimumab, a fully human anti-CTLA-4 
monoclonal antibody, is the first immunotherapeutic drug 
approved for metastatic melanoma treatment. Subsequently, 
other drugs were approved for treatment of non-small 
cell lung cancers (NSCLC), renal cell carcinomas (RCC), 
urothelial cancers, head and neck tumors, melanoma, 
Merkel cell carcinomas and microsatellite instability-
high (MSI-H) or mismatch repair deficient (dMMR) solid 
tumors. These drugs target PD-1, such as Nivolumab 
and Pembrolizumab, or PD-L1, such as atezolizumab, 
durvalumab and avelumab (2). Recently, the combination of 
nivolumab plus ipilimumab showed a survival advantage in 
treatment-naive metastatic melanoma, NSCLC and RCC 
(3-5). Moreover, combination between anti-PD1/anti-
PD-L1 and chemotherapy showed a survival benefit and a 
higher response rate in NSCLC, in small cell lung cancer 
(SCLC) and in triple negative breast cancer (6-9). The 
biological basis of this combination is based on the principle 
that chemotherapy reduces the immunosuppressive activity 
carried out by the tumor and induces the immunogenic 
tumor death, with the consequent release of molecules 
recognized as “non-self” by immune system (10).
Immunotherapy was recently studied also in adjuvant 
setting in different cancer types. In NSCLC we observed 
a reduction of the risk of death with Durvalumab after 
definitive chemoradiotherapy vs. placebo (11). In melanoma 
several phase III clinical trials evaluated ipilimumab, 
nivolumab and pembrolizumab in completely resected 
high risk patients, showing a relapse free survival (RFS) 
benefit (12,13). Further clinical trials are currently ongoing, 
testing adjuvant immunotherapy in RCC (clinicaltrials.
gov: NCT03288532), in esophageal or gastro-esophageal 
junction cancer (NCT02743494), in gastric cancer 
(NCT03443856), in head and neck cancer (NCT03406247), 
in hepatocarcinoma (NCT03630640) and in urothelial 
cancer (NCT02632409).
Pseudoprogression
Immunotherapy does not generate a rapid response like 
standard chemotherapy, but the response to treatment, 
when obtained, will last over time due to the immunological 
memory. 
New patterns of response to immunotherapy have been 
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described in literature. The first one is pseudoprogression, 
defined as a response to treatment after initial increase 
in volume of cancer lesions, due to the infiltration of 
tumoral tissue by immune cells. Overall, the rate of 
pseudoprogression do not exceed 10% in patients treated 
with immune checkpoint inhibitors (14). 
The classic response evaluation criteria in solid tumors 
(RECIST) are not applicable to immunotherapy, leading to 
formulate the immune related response criteria (irRC) and the 
immunotherapy RECIST (iRECIST). These immune-specific 
criteria imply to confirm progression with a second computed 
tomography (CT) scan and allow the appearance of new lesions 
in the definition of unconfirmed progression (15). However, 
most of clinical trials used RECIST 1.1 to assess primary 
and secondary end-points, while immune-specific criteria 
were used only for exploratory end-points, introducing a 
wide variability in the interpretation of data (14). 
It is crucial to recognize pseudoprogression from a real 
progression, to avoid both a premature discontinuation 
of an effective treatment and the delay of starting a new 
line of therapy. A tumor biopsy at the time of disease 
progression could help to assess immune system activation 
by the treatment. In a study conducted by Di Giacomo 
and colleagues, a biopsy at progression leads to identify 
a functional T-cell activation induced by treatment in 
melanoma patients receiving anti-CTLA-4 (16). Lee 
and colleagues analyzed circulating tumor DNA, that 
is associated with poor prognosis in melanoma patients 
receiving PD-1 inhibitors and showed a decrease from 
baseline in presence of pseudoprogression (17). 
Pseudoprogression seems to be associated with a 
high likelihood of 1-year survival compared to patients 
experiencing partial response, stable disease or progressive 
disease in a retrospective analysis conducted on various 
cancer type. However, it is important to underline that in 
this study the number of patients with pseudoprogression 
was small, with only 21 patients according to irRC. Larger 
analyses are required to confirm this observation (18).
Hyperprogression 
A n o t h e r  u n c o m m o n  p a t t e r n  o f  p r o g r e s s i o n  i s 
hyperprogressive disease (HPD), which is characterized 
by the acceleration of tumor growth during immune 
checkpoint inhibition. This type of progression can be the 
explanation of the cross between the survival curves during 
the first months of treatment observed in some clinical 
trials, such as that performed in non-squamous NSCLC 
patients receiving nivolumab (19). Currently, it is impossible 
to conclude if HPD is triggered by immunotherapy or is 
merely a characteristic of an aggressive disease. However, 
we can observe that HPD seems less common in patients 
receiving chemotherapy and, therefore, it is likely that it 
is a specific pattern of response to immune checkpoint 
inhibitors (20). 
HPD incidence in patients receiving immunotherapy 
range from 4% to 29% in different studies (20-23). This 
difference could be ascribed to the non-uniformity of the 
definition of HPD reported in literature, as well as to the 
heterogeneity of histology included in these studies. 
The first report on HPD has been published in 2016 
by Champiat et al. They defined HPD as a twofold or 
greater increase of tumor growth rate (TGR) during 
immunotherapy, compared to baseline. In this study, HPD 
was reported in 12 of 131 (9%) patients with different 
tumor types. No difference was observed between anti-
PD-1 and anti-PD-L1 across the different histologies, the 
number of metastasis, the tumor burden, the number and 
type of previous treatments. An association between HPD 
and older age has been observed, with a median age of 
65.5 years for HPD patients vs. 55 years for non-HPD 
(P=0.007). Patients with HPD showed a worse outcome, with 
an overall survival (OS) of 4.6 vs. 7.6 months in non-HPD 
progressive patients, although this result was not statistically 
significant due to the small number of patients (P=0.19) (21).
Kato and colleagues defined HPD as a time to treatment 
failure (TTF) <2 months, a 50% increase in tumor burden 
compared to baseline and an increase in progression 
pace greater than twofold. Notably, they performed a 
comprehensive genomic analysis, observing a strong 
association between MDM2/4 amplification and EGFR 
alterations with TTF <2 months. Overall, in this study 4 
of 6 patients (67%) with MDM2/4 amplification and 2 of 
10 patients (20%) with EGFR alterations showed HPD. 
Interestingly they observed that patients receiving anti-
CTLA-4 alone or in combination therapy were significantly 
less likely to have TTF <2 months (22). 
Saâda-Bouzid and colleagues defined HPD as a tumor 
growth kinetic ratio (TGKR) between the value during 
treatment and at baseline ≥2, where TGK was defined as 
the difference of the sum of the largest diameters on the 
target lesions per unit of time. In patients affected by head 
and neck cancer they observed an HPD rate of 29%, a 
statistically significant worse progression free survival (PFS 
according to irRECIST: 2.9 vs. 5.1 months, P=0.02) and a 
trend for shorter OS (6.1 vs. 8.1 months, P=0.77) (23).
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Ferrara and colleagues reported a retrospective analysis 
of a large series of NSCLC patients (n=465) (20). To our 
knowledge, this is the first HPD report with a control arm 
(406 patients treated with immune checkpoint inhibitors 
vs. 59 patients treated with chemotherapy) and the 
largest study focusing on a single tumor type. A different 
definition of HPD compared to that previously described in 
literature was used. In fact, HPD was defined as difference 
in TGR during treatment from baseline (∆TGR) greater 
than 50%. The authors observed HPD in 13.8% of the 
patients treated with immunotherapy vs. 5.1% in patients 
receiving chemotherapy. The incidence of HPD is probably 
underestimated in this study, due to rapid progression 
and/or death, occurred in about 76 patients, that hindered 
further CT scan evaluations. Six patients initially classified 
as hyperprogressors in the immunotherapy group, showed a 
response to treatment at subsequent CT scan. An association 
between number of metastatic sites ≥2 and HPD has been 
observed (P=0.006), but not with tumor burden. A worse 
OS has been observed in HPD patients (3.4 vs. 6.2 months 
for non-HPD progressive patients; P=0.003), accordingly 
with what reported in previous studies. In the group of 
patients receiving chemotherapy no pseudoprogression has 
been detected, while 3 patients showed HPD (5.1%). The 
authors observed a not statistically significant longer OS 
for patients with HPD compared to non-HPD progressive 
patients in chemotherapy group. However, we estimate that 
the sample size is insufficient to consider this data reliable. 
No data about association between pattern of response to 
immune checkpoint inhibitors and PD-L1 expression or 
tumor mutational burden (TBM) are available, considering 
that these molecular tests are not always mandatory in 
clinical practice. On the other hand, EGFR testing was 
available, being mandatory in clinical practice for non-
squamous histology, but no association between EGFR 
genetic alterations and HPD has been detected, contrarily 
to what reported by Kato and colleagues (22). Ferrara et 
al. analyzed also circulating biomarkers such as LDH and 
neutrophil to lymphocyte ratio (NLR), without finding any 
association with pattern of progression (20). 
A recent study by Zuazo-Ibarra et al. concluded that 
patients non-responding to anti-PD-1/PD-L1, including 
hyperprogressors, have low number of baselines circulating 
senescent CD4 T cells (Tsen). In particular, patients with 
HPD showed an aberrant systemic proliferation of Tsens 
after the first cycle of therapy, called Tsen burst (24). 
The analysis of TGR before starting treatment could 
help to identify a rapid progressive disease. Unfortunately, 
no data deriving from clinical trials about pre-treatment 
TGR are available so far. Nevertheless, some clinical trials 
showed a better benefit from immunotherapy for patients 
with a slowly progressive disease, while rapidly progressive 
NSCLC patients could benefit mostly from other type of 
treatment, such as antiangiogenetic plus chemotherapy 
(19,25). These findings, as well as the reported lower 
incidence of HPD in patients treated with chemotherapy, 
lead to speculate whether the combination between immune 
checkpoint inhibitors and chemotherapy could hamper 
HPD. Another aspect to take into consideration is about the 
therapeutic attitude in case of HPD. We know that standard 
chemotherapy lead to rapid tumor shrinkage compared to 
immunotherapy, but no data about efficacious treatment 
after HPD are reported in literature. 
In conclusion, further studies are required to analyze 
HPD during chemo-immunotherapy and to study whether 
a similar atypical pattern of response exist during adjuvant 
immunotherapy. In this setting, in fact, in which the aim of 
treatment is merely preventive, it is crucial to precociously 
identify the subgroup of patients in which immunotherapy 
could be detrimental. Moreover, molecular biomarkers 
analysis, baseline TGR association with the pattern of 
response as well as a unique definition of HDP must be 
the goals of future studies. HPD should be also included in 
evaluation criteria and its incidence should be objectively 
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